On April 22, 2020 United Therapeutics Corporation (Nasdaq: UTHR) reported that it will report its first quarter 2020 financial results before the market opens on Wednesday, April 29, 2020 (Press release, United Therapeutics, APR 22, 2020, View Source [SID1234556515]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

United Therapeutics will host a teleconference on Wednesday, April 29, 2020, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing (866) 209-9943 in the United States, with international callers dialing +1 (825) 312-2282. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing (800) 585-8367 in the United States, with international callers dialing +1 (416) 621-4642, and using access code: 1984097.

This teleconference is also being webcast and can be accessed via United Therapeutics’ website at View Source

On April 22, 2020 Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) reported that it will host a live webcast on Wednesday, May 6th at 11:30 a.m. Eastern Time to discuss its first quarter 2020 financial results and report on pipeline and business progress (Press release, Ionis Pharmaceuticals, APR 22, 2020, View Source [SID1234556514]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access the webcast at www.ionispharma.com. A webcast replay will be available for a limited time at the same address.

On April 22, 2020 Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported that The European Patent Office (EPO) has granted the Company a new patent for the composition of COM701 or backup antibodies for the treatment of cancer (Press release, Compugen, APR 22, 2020, View Source [SID1234556513]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

EPO Patent No. 3295951, titled "Anti-PVRIG Antibodies and Methods of Use," covers the composition of matter for COM701 and backup antibodies including any anti-PVRIG antibody having the binding fragments of COM701 or backup antibodies for the treatment of cancer.

The patent is expected to expire in Europe no earlier than February 2036.

About COM701

COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint discovered computationally by Compugen, and blocks the interaction with its ligand, PVRL2. TIGIT, discovered by Compugen’s computational discovery platform in 2009, and PVRIG constitute parallel immune checkpoint pathways that counteract DNAM, a costimulatory molecule on T cells and NK cells. Preclinical data suggest that the blockade of PVRIG induces a robust anti-tumor immune response and demonstrates synergistic activity when used in combination with inhibitors of TIGIT and/or PD-1. Currently, COM701 is being evaluated in a Phase 1 clinical study. Data from the ongoing study have shown that COM701 is well-tolerated and demonstrated preliminary signs of anti-tumor activity in a heavily pretreated patient population.

On April 22, 2020 Luminex Corporation (NASDAQ: LMNX) reported that it plans to report results for the first quarter ended March 31, 2020 on Monday, May 4, 2020 (Press release, Luminex, APR 22, 2020, View Source [SID1234556512]). A press release announcing the results is scheduled for release after the close of trading on that date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will hold a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2020 on May 4, 2020, at 5:00 p.m. Eastern Time.

The conference call will be webcast live and may be accessed at Luminex Corporation’s website at View Source Simply log on to the website, go to the About Luminex section and access the Investor Relations link. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the ‘replay’ link.

On April 22, 2020 Immunovia reported that invites to a teleconference (in English) for investors, analysts and media on Tuesday, April 28th, 2020 at 16:30 CET (Press release, Immunovia, APR 22, 2020, View Source;march-2020-on-april-28-2020-301045422.html [SID1234556511]). Immunovia will publish the company’s interim report on April 28th, 2020 at 16:00 CET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mats Grahn, CEO will present Immunovia and comment on the interim report for the period January – March 2020 followed by a Q&A session.

Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator:

Immunovia Webcast: https://channel.royalcast.com/webcast/immunovia/20200401_1/

There will be an MP3-file available at Immunovia’s webpage under Investors/Financial Reports (View Source) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.